Cian Healthcare Limited has announced the constitution of a Resolution Plan Implementation Committee following the approval of its resolution plan by the National Company Law Tribunal (NCLT). The pharmaceutical company, currently under Corporate Insolvency Resolution Process, informed BSE Limited about this development on December 20, 2025.

NCLT Approval and Committee Formation

The Resolution Plan Implementation Committee has been constituted with effect from December 18, 2025, the date when the Honourable National Company Law Tribunal Bench-VI, Mumbai approved the company's resolution plan. The committee will remain operational until the Resolution Plan Closure Date as defined under the provisions of the approved resolution plan.

The committee formation follows the company's earlier intimation dated December 19, 2025, regarding the NCLT approval under the provisions of the Insolvency and Bankruptcy Code, 2016.

Committee Composition and Leadership

The Implementation Committee comprises three key members representing different stakeholder groups:

Mr. Roshen Chordiya, who previously served as the Resolution Professional of Cian Healthcare Limited, will chair the committee. He holds IBBI Registration No. IBBI/IPA-001/IP-P02840/2023-2024/14347.

Powers and Responsibilities

The Implementation Committee has been entrusted with comprehensive authority to oversee the resolution plan implementation. The committee's primary responsibilities include:

• Overseeing the implementation of the approved resolution plan
• Ensuring timely discharge of payments to stakeholders
• Supervising payment processes as per approved resolution plan terms
• Executing administrative decisions for operational continuity
• Facilitating statutory and ancillary filings
• Ensuring adherence to applicable laws and NCLT directions

The committee has been empowered with authority equivalent to that of the Board of Directors, as outlined in the Companies Act, 2013, along with relevant provisions of Listing Regulations and other applicable regulations.

Temporary Governance Structure

The powers granted to the Implementation Committee are temporary in nature and strictly limited to the Resolution Plan Implementation Period. These powers will automatically cease upon completion of the resolution plan implementation on the Resolution Plan Closure Date.

The structured governance mechanism through this committee ensures transparent execution, stakeholder protection, and effective monitoring until full implementation of the approved resolution plan is completed. The company has clarified that this arrangement does not affect stakeholder rights beyond what is provided under the approved resolution plan.

Corporate Details

Cian Healthcare Limited operates as an ISO 9001:2015 and WHO GMP certified pharmaceutical company. The company's registered office is located in Pune, Maharashtra, while its manufacturing facility is situated in Haridwar, Uttarakhand.

Cian Healthcare Limited successfully conducted its 22nd Annual General Meeting on December 17, 2025, where shareholders unanimously approved key corporate governance matters including the adoption of FY25 financial statements and important auditor appointments. The meeting was held through video conferencing under the chairmanship of Resolution Professional Roshen Chordiya, reflecting the company's current status under Corporate Insolvency Resolution Process (CIRP).

AGM Proceedings and Attendance

The virtual meeting commenced at 10:00 AM IST and concluded at 10:40 AM IST, including a 15-minute e-voting period. The company had 1,723 members as of the December 10, 2025 cut-off date. Key attendees included Resolution Professional Roshen Chordiya as Chairman, suspended Managing Director Suraj Shriniwas Zanwar, and key managerial personnel including Compliance Officer Bhushan Ramesh Kulkarni and Chief Financial Officer Kalyani Vijay Chordia.

Key Resolutions Approved

Shareholders approved three ordinary resolutions with unanimous support, demonstrating strong confidence in the proposed corporate actions:

The first resolution involved adopting audited standalone and consolidated financial statements for the financial year ended March 31, 2025, including Balance Sheet, Statement of Profit & Loss, Cash Flow Statement, and Statement of changes in Equity, along with the Resolution Professional's report and Auditors' report.

Auditor Appointments and Professional Services

A significant development was the appointment of KNG C and Associate LLP as secretarial auditors for a five-year term. The firm brings over five years of professional experience specializing in secretarial audit, due diligence, assurance audit, corporate compliance management, representation services, and transaction advisory services.

Additionally, shareholders ratified the remuneration of Suraj Lahoti Associates (FRN: 101489) as Cost Auditor for the financial year 2025-2026, ensuring continuity in the company's audit framework.

Voting Process and Results

The company provided both remote e-voting and e-voting during the AGM to ensure maximum shareholder participation. The remote e-voting period was conducted from December 13, 2025 (9:00 AM) to December 16, 2025 (5:00 PM), with additional voting facility available during the meeting.

Nikhil Umesh Karwa, Partner at KNG C and Associate LLP, served as the scrutinizer for the voting process. All three resolutions received 647,784 votes in favor with zero votes against, representing 100% approval from participating shareholders. The voting results demonstrated strong shareholder confidence despite the company's CIRP status.

Corporate Governance Under CIRP

The meeting highlighted the company's commitment to maintaining corporate governance standards while under Corporate Insolvency Resolution Process. Resolution Professional Roshen Chordiya provided insights into the company's background, CIRP status, and financial performance for 2024-25, along with operational highlights and future outlook.

The successful conduct of the AGM with unanimous approval of all resolutions indicates stakeholder confidence in the resolution process and the company's governance framework during this transitional period.